Document:

EX-10.17

 Exhibit 10.17 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 14-111 

15-0897 
 LICENSE AGREEMENT 

Between: THE UNIVERSITY OF BRITISH COLUMBIA 

and 
 GENOMEDX BIOSCIENCES INC. 

Table of Contents 
  

							
	Article	 	 	  	Page	 
			
	 1.0
	 	 DEFINITIONS
	  	 	2	 
	 2.0
	 	 PROPERTY RIGHTS IN & TO THE TECHNOLOGY
	  	 	7	 
	 3.0
	 	 GRANT OF LICENSE
	  	 	7	 
	 4.0
	 	 SUBLICENSING
	  	 	8	 
	 5.0
	 	 ROYALTIES
	  	 	8	 
	 6.0
	 	 ANNUAL LICENSE FEE
	  	 	10	 
	 7.0
	 	 PATENTS
	  	 	10	 
	 8.0
	 	 DISCLAIMER OF WARRANTY
	  	 	11	 
	 9.0
	 	 INDEMNITY & LIMITATION OF LIABILITY
	  	 	12	 
	 10.0
	 	 PUBLICATION & CONFIDENTIALITY
	  	 	13	 
	 11.0
	 	 PRODUCTION & MARKETING
	  	 	14	 
	 12.0
	 	 ACCOUNTING RECORDS & REPORTS
	  	 	14	 
	 13.0
	 	 INSURANCE
	  	 	15	 
	 14.0
	 	 ASSIGNMENT
	  	 	16	 
	 15.0
	 	 GOVERNING LAW
	  	 	16	 
	 16.0
	 	 NOTICES
	  	 	16	 
	 17.0
	 	 TERM
	  	 	17	 
	 18.0
	 	 TERMINATION OF AGREEMENT
	  	 	17	 
	 19.0
	 	 MISCELLANEOUS COVENANTS OF LICENSEE
	  	 	18	 
	 20.0
	 	 MANAGEMENT OF CONFLICTS OF INTEREST
	  	 	19	 
	 21.0
	 	 GENERAL
	  	 	20	 

 Schedules 
  

	 	“A”	 Description of “Technology” 

	 	“B”	 Payment Report 

	 	“C”	 UBC License Agreement Annual Report 

	 	“D”	 Address for Notices & Payment Instructions 

	 	“E”	 Patent Client and Billing Agreement 

	 	“F”	 List of Licensed Affiliated Companies 

	 	“G”	 Mandatory Sublicensing Provisions 

 UBC File:14-111 

LICENSE AGREEMENT 
 BETWEEN: 

THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at #103-6190
Agronomy Road, Vancouver, British-Columbia, V6T 1Z3 
 (“UBC”) 

AND: 
 GENOMEDX BIOSCIENCES INC., a
corporation incorporated under the Business Incorporation Act of British Columbia, with its offices at 1038 Homer St. Vancouver, BC, V6B 2W9 

(the “Licensee”) 
 WHEREAS: 

A. UBC has been engaged in Licensee sponsored research (UBC UILO CRA F11-044153) during the course of which it has invented and/or developed
certain technology relating to “Cancer Biomarkers and Classifiers and Uses Thereof’ (UBC UILO file 14-111), which research was undertaken by Peter Black (the “Investigator”) in the UBC Department of
Urologic Sciences; 
 B. The Licensee was granted an option to obtain a royalty bearing license to IP created under UBC CRA F11-044153, signed
October 1, 2011; 
 C. It is UBC’s objective to exploit its technology for the public benefit, and in a manner consistent with its Global
Access Principles, and status as a non-profit, tax exempt educational institution; and 
 C. The Licensee and UBC have agreed to enter into this license on the terms
and conditions set out in this Agreement. 
 THE PARTIES AGREE AS FOLLOWS: 
  

	1.0	 DEFINITIONS 

  

	1.1	 In this Agreement: 

  

	 	(a)	 “Affiliated Company” or “Affiliated Companies” means two or more corporations if the
relationship between them is one in which one of them is a subsidiary of the other, or both are subsidiaries of the same corporation, or 50% or more of the voting shares of each of them is owned or controlled by the same person, corporation or other
legal entity; 

  

	 	(b)	 “Agreement” means this license agreement; 

 

	 	(c)	 “Annual License Fee” is defined in Article 6.1; 

 

	 	(d)	 “Annual Report” means a report in the form referred to in Article 12; 

  
 Page 2 of 32 

 UBC File:14-111 
  

 

	 	(e)	 “Combination Product” means products commercialized by the Licensee that: 

 

	 	(i)	 include the Technology and/or any Improvements; 

 

	 	(ii)	 and one or more components, products or modules that have commercial utility and functionality separate from the
Technology and any Improvements, and when or if-such-components, products or modules are sold as stand-alone items, they would not infringe the Patents licensed under this Agreement (“Non-Covered Components”). 

 

	 	(f)	 “Confidential Information” means all information, regardless of its form, disclosed by one party to
the other and identified as “confidential” at the time of disclosure, except that “Confidential Information” does not include information: 

 

	 	(i)	 possessed by the recipient (the “Recipient”) before receipt from the disclosing party (the
“Discloser”), other than through prior disclosure by the Discloser, as evidenced by the Recipient’s business records; 

  

	 	(ii)	 published or available to the general public otherwise than through a breach of this Agreement; 

 

	 	(iii)	 obtained by the Recipient from a third party with a valid right to disclose it, provided that the third party is not
under a confidentiality obligation to the Discloser; or 

  

	 	(iv)	 independently developed by employees, agents or consultants of the Recipient who had no knowledge of or access to the
Discloser’s information as evidenced by the Recipient’s business records; 

 all information and documents
related to the Technology (including all derived analyses and conclusions), and the terms and conditions of this Agreement will be deemed Confidential Information of both parties. 

 

	 	(g)	 “Effective Termination Date” means the date on which this Agreement is terminated under Article 18;

  

	 	(h)	 “First Use of the Technology” means the earlier of either: 

 

	 	(i)	 the first use of the Technology or any Improvement, or 

 

	 	(ii)	 the first sale of a Product, 

in exchange for valuable consideration; 
  

	 	(i)	 “Improvements” means unencumbered improvements, variations, updates, modifications, and enhancements
made and/or acquired at any time after the Start Date by: 

  

	 	(i)	 the Investigator while employed at UBC, 

the Licensee , or 
  

	 	(ii)	 jointly, by the Investigator while employed at UBC, and the Licensee or any Sublicensees,

  
 Page 3 of 32 

 UBC File:14-111 
  

	 	 relating to the Technology which cannot be legally used or practiced without infringing the Patents licensed under this
Agreement; 

  

	 	(j)	 “Investigator” is defined in Recital “A”; 

 

	 	(k)	 “Multi-marker Product” is defined in Article 5.2; 

 

	 	(l)	 “Objectionable Material” is defined in Article 10.3; 

 

	 	(m)	 “Patents” means collectively the rights in and to any and all inventions which are disclosed in the
Canadian, U.S., and foreign patents and patent applications identified in Schedule “A” and all: 

  

	 	(i)	 counterparts, continuations, continuations-in-part, divisionals, continuing prosecution applications, and requests for
continued examinations, extensions, term restorations, renewals, reissues, re-examinations, or substitutions thereof; 

  

	 	(ii)	 corresponding international patent applications; 

 

	 	(iii)	 corresponding foreign patent applications, including supplementary protection certificates and other administrative
protections; and 

  

	 	(iv)	 international and foreign counterpart patents, 

resulting therefrom, all of which will be deemed added from time to time to Schedule “A”; 

 

	 	(n)	 “Payment Report” means a report in the form referred to in Article 12 setting out in detail how the
amount of Revenue and Sublicensing Revenue was determined; 

  

	 	(o)	 “Product(s)” means goods or services manufactured or provided in connection with the use of
all or some of the Technology and/or any Improvements, including Multi-marker Products; 

  

	 	(p)	 “Revenue” shall mean, subject to the adjustment set forth in Sections 5.3 and 5.4, the gross amount
of cash, cash equivalents, or in kind consideration of readily ascertainable value (for purposes of clarity, in kind consideration does not include any services received by Licensee or its Affiliated Companies from, or activities conducted by, a
third party pertaining to marketing, market development, promotions, advertising, training, education, outreach, clinical or validation studies, research, development and regulatory activities, unless those services were provided in lieu of payment
for Products or in lieu of royalties otherwise due from Sublicensees (in which case the fair market value of such services are to be included in Revenue or Sublicensing Revenue as the case may be)), received by Licensee, or its Affiliated Companies
for the transfer or provision of a Product to a third party (but not including Sublicensing Revenue), less documented: 

  

	 	(i)	 import, export, sales, excise or use taxes or duties, as well as freight, insurance and other shipping expenses, in
all such cases to the extent shown on the face of a Product invoice; 

  
 Page 4 of 32 

 UBC File:14-111 
  

 

	 	(ii)	 credits and refunds for defective or returned, rejected or recalled Products actually given; 

 

	 	(iii)	 regular trade, quantity, cash or other discounts, allowances, incentives, chargebacks, rebates and price reductions
actually given and reimbursement limitations actually imposed and incurred regarding a Product (in all such cases, whether-retroactively, contemporaneously or on a reasonably anticipated basis); and 

 

	 	(iv)	 actual allowances for bad debt or uncollectible amounts regarding sales of Products (provided that such allowances
have been formally designated as such in accordance with the Licensee’s internal accounting procedures consistently applied) to the extent included in amounts received by the Licensee. 

If not received in cash, other consideration received by the Licensee, or its Affiliated Companies to be used in calculating Revenue
shall be the fair market value of such other consideration. Revenue shall not include any amount for the sale or other transfer or provision of any Product to, by or between the Licensee and its Affiliated Companies unless the receiving party is the
end user of the Product, provided that any subsequent resale or re-transfer of such Product to an end user of the Product shall be included in Revenue. Revenue shall be determined from the books and records of Licensee and/or its Affiliated
Companies maintained in accordance with U.S. generally accepted accounting principles consistently applied. For the avoidance of doubt, any transfer or provision of Products at or below the manufacturing cost for use as samples, demonstration,
marketing or promotional purposes or research and development (including for clinical trials) shall not be deemed or give rise to Revenue. 
  

	 	(q)	 “Royalty Due Dates” means the last day of June and December of each year during the Term;

  

	 	(r)	 “Start Date” means 14 November, 2014; 

 

	 	(s)	 “Sublicensee” means any third party who has obtained directly or indirectly from or through the
Licensee any commercial rights to the Technology, any Improvements or Product, and shall include all sublicensees, that have entered into agreements with the Licensee for the use, development, evaluation,
co-development, partnered development, manufacture, distribution, marketing or sale of Products or granting rights to such third party in the Technology or any Improvements; 

 

	 	(t)	 “Sublicensing Revenue” means consideration directly or indirectly collected or received (including
without limitation royalties, initial, or periodic license fees, option payments, standstill payments, development or commercialization fees (subject to subsection (ii) below), milestone payments or any other payments unless excluded in this
definition) that Licensee receives or collects from a Sublicensee directly attributable to the grant of a sublicense to the Technology, any Improvements or Products, whether received in cash or other form, including amounts paid in excess of the
fair market value of any shares or other securities. For the avoidance of doubt: 

  
 Page 5 of 32 

 UBC File:14-111 
  

	 	(i)	 Sublicensing Revenue does not include 

 

	 	(A)	 the fair market value of payments or other consideration received for debt or equity; or 

 

	 	(B)	 reimbursement of costs or expenses actually incurred by Licensee. 

 

	 	(ii)	 Sublicensing Revenue will include all research or development fees received by the Licensee in connection with the
Technology, any Improvement, or any Products, in excess of the direct reimbursement for the actual costs of such research and development; 

  

	 	(iii)	 if a sublicense agreement to a Sublicensee includes either: 

 

	 	(A)	 a sublicense of one or more other biomarkers licensed to the Licensee under a royalty-bearing license with one or more
arm’s length third parties (other than from one of the Licensee’s own Sublicensees); and/or 

  

	 	(B)	 one or more biomarkers developed independently by the Licensee; 

and only to the extent such biomarker(s), whether licensed from a third party or developed independently by the Licensee, increase the
overall performance of a sublicensed Product, (a “Multi-marker Sublicense”), then the Sublicensing Revenue received by the Licensee under the Multi-Marker Sublicense shall be determined by multiplying the total Sublicensing Revenue
received under the Multi-marker Sublicense by the fraction A / (A + B), in which “A” is the number of biomarkers licensed to the Licensee under this Agreement, and “B” is the number of biomarkers licensed by the Licensee from one
or more arm’s length third parties (other than from one of its sublicensees) or those biomarkers developed independently by the Licensee (but only to the extent such biomarkers increase the overall performance of the Product), provided that the
fraction shall never be less than [***]. 
  

	 	(u)	 “Technology” means the Patents and all knowledge, know-how and/or technique or techniques invented,
developed and/or acquired, before the Start Date by the Investigator while employed at UBC or by the Licensee relating to, and including, the technology and materials described in Schedule “A”, as amended from time to time,
including, without limitation all related research, data, specifications, instructions, manuals, papers or other related materials of any nature at all, whether written or otherwise, and UBC’s Confidential Information; 

 

	 	(v)	 “Term” is defined in Article 17.1; and 

 

	 	(w)	 “Trade-marks” means any mark, trade-mark, service mark, logo, insignia, seal, design, symbol or
device used by UBC or Licensee in any manner at all. 

  

	 	(x)	 “Valid Claim” means (a) a claim of a pending application of the Patents or Licensee Patent(s)
which claim has been pending for [***] years or less, is being actively prosecuted in good faith and has not lapsed or gone abandoned; 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 6 of 32 

 UBC File:14-111 
  

	 	 (b) a claim of an issued or granted patent of the Patents or Licensee Patent(s)which claim has not expired, been
abandoned (including via admissions of invalidity and/or unenforceability), lapsed or been found to be invalid or unenforceable in a final decision of a court or other authority or agency of competent jurisdiction from which no appeal can be or is
taken; or (c) a supplementary protection certificate resulting from the expiry of an issued claim. 

  

	2.0	 PROPERTY RIGHTS IN & TO THE TECHNOLOGY 

2.1 UBC and the Licensee acknowledge and agree that the invention claimed in the [***] is jointly owned by UBC and the Licensee. 

2.2 Any Improvement made by UBC and the Licensee jointly in the course of practicing the Technology shall be jointly owned by UBC and the Licensee. 

2.3 On the last working day of December of each year during the Term, the Licensee will give notice to UBC of the details of all Improvements made by
the Licensee along with a summary report of activities conducted by the Licensee and any Sublicensees to practice and/or exploit the Technology during the previous year. 
  

	3.0	 GRANT OF LICENSE 

3.1 Subject to Article 3.3, UBC grants to the Licensee a worldwide, exclusive license to use and sublicense the Technology and any Improvements and to
manufacture, have made, distribute, sell, offer for sale, import, and export the Products on the terms and conditions set out in this Agreement. 

3.2 The license granted under this Agreement is granted only to the Licensee and any Affiliated Companies of the Licensee listed in Schedule
“F”, provided that: 
  

	 	(a)	 each Affiliated Company will perform the terms of this Agreement as if such Affiliated Company were a signatory to
this Agreement and each Affiliated Company agrees with UBC as primary obligor, to adopt as its own obligations every obligation of the Licensee contained or set forth in this Agreement; 

 

	 	(b)	 the Licensee unconditionally guarantees the performance of each Affiliated Company with the terms and conditions of
this Agreement; 

  

	 	(c)	 Affiliated Companies shall, at Licensee’s election, either by itself or through consolidated accounting with
Licensee, account for, and report, their sales of Product and receipts of Revenue on the same basis as if such sales or Revenues were the sales or Revenues of the Licensee, which shall then be included in the calculation of royalties due to UBC
under this Agreement; 

  

	 	(d)	 the obligations and liabilities of each Affiliated Company and the Licensee under this Agreement shall be joint and
several and UBC shall not be obliged to seek recourse against any Affiliate Company before enforcing its rights against the Licensee; and 

  

	 	(e)	 the Affiliated Companies shall not further sublicense the Technology or any Improvements or enter into sublicense
agreements with Sublicensees. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 7 of 32 

 UBC File:14-111 
  

The Licensee may amend Schedule “F” from time to time on written notice to UBC to include additional Affiliated Companies of the
Licensee. 
 3.3 The Licensee acknowledges and agrees that UBC may use the Technology and any Improvements without charge in any manner at all
for internal and non-commercial research, scholarly publication, educational and all other non-commercial uses. 
  

	4.0	 SUBLICENSING 

4.1 The Licensee may grant sublicenses of the Technology and/or any Improvements to Sublicensees without the prior written consent of UBC,
provided that each such sublicense agreement contain the mandatory sublicensing provisions set out in Schedule “G”. The Licensee will provide UBC with a signed copy of each sublicense agreement within 30 days of it being signed by
the Licensee and the Sublicensee provided that Licensee shall have the right to redact such sublicense agreement so long as the redacted copy is sufficient for UBC to verify Licensee’s compliance with this Section 4.1. 

4.2 Any sublicense agreement granted by the Licensee in full compliance with the requirements of this Agreement may be further sub-sublicensed without
the prior written consent of UBC, provided that such further sub-sublicense agreements also comply with the requirements of this Agreement, including without limitation the provisions of Article 4.1 applied mutatis mutandis to such
sub-sublicense agreement. 
  

	5.0	 ROYALTIES 

5.1 In consideration of the license granted under this Agreement, the Licensee will pay to UBC a royalty equal to [***]% of the Revenue. The
Licensee’s obligation to pay royalties on the Revenue shall commence on the date of the first sale of a Product by the Licensee and shall continue, on a Product-by-Product basis, until the expiration (or invalidation or unenforceability, as the
case may be) of the last Valid Claim within an issued Patent licensed under this Agreement covering the using or selling of such Product, after which time no royalties on the Revenue shall be due for the sale of such Product. 

5.2 In consideration of the license granted under this Agreement, the Licensee will pay to UBC a royalty equal to [***]% of the Sublicensing Revenue.

 5.3 If any product sold by the Licensee contains, in addition to one or more biomarkers licensed to the Licensee under this
Agreement, one or more royalty-bearing biomarkers licensed by the Licensee from one or more arm’s length third parties (other than from one of its Sublicensees) or those biomarkers were developed independently by the Licensee (and only to the
extent such biomarkers, whether licensed from a third party or developed independently by the Licensee, increase the overall performance of the Product) (a “Multi-marker Product”), then the Revenue attributable to the biomarker
licensed to the Licensee under this Agreement shall for the purposes of calculating the royalty payable in Article 5.1 be determined by multiplying the total Revenue received from the sale of the Multi-marker Product by the fraction A / (A + B), in
which “A” is the number of biomarkers licensed to the Licensee under this Agreement, and “B” is the number of biomarkers licensed by the Licensee from one or more arm’s length third parties (other than from one of its
sublicensees) or those biomarkers developed independently by the Licensee (but only to the extent such biomarkers increase the overall performance of the Product), provided that the fraction shall never be less than [***]. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 8 of 32 

 UBC File:14-111 
  

 

	 	(a)	 If any product sold by the Licensee in any country is in the form of a Combination Product, the Revenue attributable
to the license under this Agreement from the sale of such Combination Product shall be adjusted down by multiplying the actual total Revenue from such Combination Product in such country by the fraction A / (A + B) where A is the average invoice
price in such country of a Product containing the same amount of Product that is included in such Combination Product sold without the Non-Covered Components, when sold separately in such country, and B is the average invoice price of the Non-
Covered Component(s) containing the same amount of such Non-Covered Component that is included in such Combination Product in such country, when sold separately in such country. If, on a country-by-country basis, either the Product is not sold
without the Non-Covered Components and/or the Non- Covered Components are not sold separately, Revenue for the purpose of determining royalties of the Combination Product owed under this Agreement shall be reasonably determined in good faith based
on the relative values of the Non-Covered Components and the Product components. 

  

	 	(b)	 for the purposes of calculating the downward reduction, the fraction A / (A + B) shall never be less than [***].

 5.4 The royalty is due and payable within 30 days of each respective Royalty Due Date and is to be calculated with respect to the
Revenue and the Sublicensing Revenue in the six month period immediately before the applicable Royalty Due Date. For greater clarity it is confirmed that the [***]% royalty payable on Revenue under Article 5.1 will be calculated and payable by the
Licensee on both Revenue received by the Licensee, and on a “reach through” basis on all Revenue received by any Affiliated Companies, and the Licensee shall require all Affiliated Companies to completely and accurately report all such
Revenue, directly to UBC or through consolidated report by Licensee, at Licensee’s election. 
 5.5 All royalties paid by the Licensee to UBC
under this Agreement will be in U.S. dollars without any reduction or deduction of any nature or kind at all except as specifically set forth in this Agreement. If the Licensee receives any Revenue or Sublicensing Revenue in a currency other than US
dollars, the currency will be converted to the equivalent in US dollars on the date that any amount is payable to UBC, at the rate of exchange set by the Bank of Canada for buying Canadian dollars with such currency. The amount of US dollars
resulting from the conversion is to be included in Revenue or Sublicensing Revenue. 
 5.6 In addition to the above payments, the Licensee will pay to UBC milestone
payments of 
  

	 	(a)	 $[***] upon the first commercial sale (by the Licensee, any Affiliated Company or any Sublicensee) of the first
Product; 

  

	 	(b)	 $[***] once cumulative Revenue reaches $[***]; and 

 

	 	(c)	 $[***] once cumulative Revenue reaches $[***]. 

For clarity: a) each milestone payment referred to in this Article 5.7 will be payable once only, regardless of how many Products achieve such milestone
event; and b) for the purposes of calculating the $[***] and $[***] milestones, the cumulative Revenue from Multi- marker Products and Combination Products shall be subject the reductions set out in Articles 5.3 and 5.4. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 9 of 32 

 UBC File:14-111 
  

 

	6.0	 ANNUAL LICENSE FEE 

6.1 The Licensee will pay to UBC, in addition to all other amounts due under this Agreement, an annual license fee of $[***] (Canadian
funds) (the “Annual License Fee”). The Annual License Fee is payable, in advance, on or before January 1 of each year during the Term, starting on January 1, 2018 and will not be refunded to the Licensee (in whole or in
part) under any circumstances. 
  

	7.0	 PATENTS 

7.1 Subject to UBC’s approval, the Licensee will, after the execution of Schedule “E” by the appropriate parties, be
responsible for preparing, filing, prosecuting and maintaining the [***] jointly in UBC’s and the Licensee’s name and other patents claiming or covering the Technology or any Improvements in UBC’s name (the “Patent
Management”), and will ensure that the Patents broadly claim for UBC’s benefit all inventions disclosed by the Technology and any Improvements. The License will use its own patent counsel for the drafting and preparation of all
documents, filings, responses and correspondence, and UBC’s patent counsel (as identified in Schedule E) shall be the counsel of record with the patent agency and shall perform solely administrative functions such as calendaring, filing and the
like, as instructed by Licensee or its patent counsel in writing. The Licensee will provide to UBC all material information and documents received, prepared or filed in connection with the Patents. The Licensee agrees to use reasonable efforts to
include all reasonable comments and changes required by UBC as appropriate. 
 If the Licensee intends to abandon, allow to lapse, or not
continue the Patent Management of a Patent in any country, then the Licensee will not less than 60 days before any required action relating to such Patent notify UBC and UBC will then have the right, at its option, to assume the Patent Management of
such Patent, in which case such Patent will be excluded from the Patents licensed under this Agreement and Licensee will assign without further consideration its interest in such Patent (if jointly owned by the Licensee) to UBC. 

7.2 To assist the Licensee with the Patent Management, UBC will at the reasonable request of the Licensee, provide required information and will execute
and deliver documents and do such other reasonable acts as the Licensee may request. The Licensee will reimburse UBC for all reasonable costs incurred in complying with such requests. If there is any dispute between UBC and the Licensee relating to
any decision in connection with the Patents or the Patent Management then 
  

	 	(a)	 the Licensee will have the right to make the final decision to resolve such dispute on Patents that are jointly owned
by UBC and Licensee. 

  

	 	(b)	 UBC will have the right to make the final decision to resolve such dispute on Patents that are solely owned by UBC.

 7.3 Within 30 days of the date of any UBC invoice, the Licensee will reimburse UBC for [***] Patent expenses incurred by UBC both
before and after the Licensee has assumed the Patent Management. 
 7.4 The Licensee will not contest the validity or scope of any Patents licensed under this
Agreement. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 10 of 32 

 UBC File:14-111 
  

7.5 The Licensee will ensure proper patent marking for all uses of the Technology and any Improvements licensed under this Agreement and will clearly
mark the appropriate Patent numbers on any Products made using the Technology and any Improvements. 
  

	8.0	 DISCLAIMER OF WARRANTY 

8.1 UBC makes no representations, conditions or warranties, either express or implied, regarding the Technology or any Improvements or the Products.
Without limitation, UBC specifically disclaims any implied warranty, condition or representation that the Technology or any Improvements or the Products: 
  

	 	(a)	 correspond with a particular description; 

 

	 	(b)	 are of merchantable quality; 

 

	 	(c)	 are fit for a particular purpose; or 

 

	 	(d)	 are durable for a reasonable period of time. 

UBC is not liable for any loss, whether direct, consequential, incidental or special, which the Licensee or other third parties suffer arising from any
defect, error or fault of the Technology or any Improvements or Products, or their failure to perform, even if UBC is aware of the possibility of the defect, error, fault or failure. The Licensee acknowledges that it has been advised by UBC to
undertake its own due diligence regarding the Technology, any Improvements or Products. 
 8.2 Nothing in this Agreement: 

 

	 	(a)	 constitutes a warranty or representation by UBC as to title to the Technology or any Improvements or that anything
made, used, sold or otherwise disposed of under the license granted in this Agreement will not infringe the patents, copyrights, trade-marks, industrial designs or other intellectual property rights of any third parties, or any patents, copyrights,
trade-marks, industrial design or other intellectual property rights owned, in whole or in part, by UBC, or licensed by UBC to any third parties; 

  

	 	(b)	 constitutes an express or implied warranty or representation by UBC that the Licensee has, or will have the freedom to
operate or practice the Technology or any Improvements, or the freedom to make, have made, use, sell or otherwise dispose of Products; or 

  

	 	(c)	 imposes an obligation on UBC to bring, prosecute or defend actions or suits against third parties for infringement of
patents, copyrights, trade-marks, industrial designs or other intellectual property or contractual rights. 

 8.3 Notwithstanding
Article 8.2, if there is an alleged infringement of the Technology or any Improvements or any right with respect to the Technology or any Improvements, the Licensee may, on receiving the prior written consent of UBC, prosecute litigation designed to
enjoin infringers of the Technology or any Improvements. Provided that it has first granted its prior written consent, UBC agrees to reasonably co-operate to the extent of signing all necessary documents and to vest in the Licensee the right to
start the litigation, provided that all the direct and indirect costs and expenses of bringing and conducting the litigation or settlement are paid by the Licensee. All amounts recovered by the Licensee as the result of such litigation

  
 Page 11 of 32 

 UBC File:14-111 
  

will accrue to the benefit of the Licensee, provided that such amounts will be included in the Licensee’s Revenue and subject to payment of a
royalty to UBC in accordance with Article 5. 
 8.4 If any complaint alleging infringement of any patent or other proprietary rights is made against
the Licensee or a Sublicensee of the Licensee regarding the use of the Technology or any Improvements or the development, manufacture, use or sale of the Products, the following procedure will be adopted: 

 

	 	(a)	 the Licensee will promptly notify UBC on receipt of the complaint and will keep UBC fully informed of the actions and
positions taken by the complainant and taken or proposed to be taken by the Licensee on behalf of itself or a Sublicensee; 

  

	 	(b)	 except as provided in Article 8.4(d), all costs and expenses incurred by the Licensee or any Sublicensee of the
Licensee in investigating, resisting, litigating and settling the complaint, including the payment of any award of damages and/or costs to any third party, will be paid by the Licensee or any Sublicensee of the Licensee, as the case may be;

  

	 	(c)	 no decision or action concerning or governing any final disposition of the complaint will be taken without full
consultation with, and approval by, UBC; and 

  

	 	(d)	 UBC may elect to participate as a party in any litigation involving the complaint to the extent that the court may
permit, but any additional expenses generated by such participation will be paid by UBC (subject to the possibility of recovery of some or all of the additional expenses from the complainant), 

 

	9.0	 INDEMNITY & LIMITATION OF LIABILITY 

9.1 The Licensee indemnifies, holds harmless and defends UBC, its Board of Governors, officers, employees, faculty, students, invitees and agents against
any and all claims (including all associated legal fees and disbursements actually incurred) arising out of the exercise of any rights under this Agreement, including without limitation against any damages or losses, consequential or otherwise,
arising in any manner at all from or out of the use of the Technology or any Improvements or Products licensed under this Agreement by the Licensee or its Sublicensees or their customers or end-users. 

9.2 UBC’s total liability, whether under the express or implied terms of this Agreement, in tort (including negligence) or at common law, for any
loss or damage suffered by the Licensee, whether direct, indirect or special, or any other similar damage that may arise or does arise from any breaches of this Agreement by UBC, its Board of Governors, officers, employees, faculty, students or
agents, is limited to $10,000. 
 9.3 The parties acknowledges and agrees that neither party will be liable for consequential or incidental damages
arising from any breach or breaches of this Agreement, provided that the limitation set out in this Article 9.3: 
  

	 	(a)	 will not apply to limit the Licensee’s obligation to indemnify under Article 9.1; and 

 

	 	(b)	 will not apply to limit the Licensee’s liability to pay all financial obligations to UBC under this Agreement,
including without limitation royalties, milestone payments and the Annual License Fee or any other amounts due under this Agreement. 

  
 Page 12 of 32 

 UBC File:14-111 
  

9.4 Notwithstanding the termination or expiration of this Agreement, the rights and obligations in Article 9 will survive and continue to bind the
Licensee and its successors and permitted assigns. 
  

	10.0	 PUBLICATION & CONFIDENTIALITY 

10.1 Each party will keep and use the other party’s Confidential Information in confidence and will not, without the other party’s prior
written consent, disclose the other party’s Confidential Information to any person or entity, except to the party’s directors, officers, employees, faculty, students, actual and/or potential collaborators, investors and acquirers and
professional advisors who require the Confidential Information to assist such party in exercising its rights or performing its obligations under this Agreement or otherwise conducting its business. Each party will maintain an appropriate internal
program limiting the distribution of Confidential Information to only those officers, employees, actual and/or potential collaborators, investors, acquirers and professional advisors who require such Confidential Information in performing the
Licensee’s obligations under this Agreement and who have signed appropriate non-disclosure agreements. 
 10.2 Any party required by judicial or
administrative process to disclose the other party’s Confidential Information, will promptly notify the other party and allow it reasonable time to oppose the process before disclosing the Confidential Information. 

10.3 UBC is not restricted from presenting at symposia, national or regional professional meetings, or from publishing in journals or
other publications, accounts of its research relating to the Technology and any Improvements, provided that with respect to the Confidential Information only, the Licensee is provided with copies of the proposed disclosure at least 60 days before
the presentation or publication date and does not, within 30 days after delivery of the proposed disclosure, give notice to UBC indicating that it objects to the proposed disclosure. Any objection to a proposed disclosure will specify the portions
of the proposed disclosure considered objectionable (the “Objectionable Material”). On receiving notice from the Licensee that any proposed disclosure contains Objectionable Material, UBC and the Licensee agree to work together to
revise the proposed disclosure to remove or alter the Objectionable Material in a manner acceptable to both the Licensee and UBC, in which case the Licensee will withdraw its objection. UBC is not restricted from publishing or presenting the
proposed disclosure as long as the Objectionable Material has been removed. Any Objectionable Material will not be disclosed for 6 months from the date UBC delivered the proposed disclosure to the Licensee. After 6 months from the date UBC delivered
the proposed disclosure to the Licensee, UBC is free to present and/or publish the proposed disclosure whether or not it contains Objectionable Material. 

10.4 The Licensee requires of UBC, and to the extent permitted by law UBC agrees, that this Agreement, and each part of it, is confidential and will not
be disclosed to third parties, as the Licensee claims that the disclosure would or could reveal commercial, scientific or technical information and would significantly harm the Licensee’s competitive position and/or interfere with the
Licensee’s negotiations with prospective Sublicensees. Notwithstanding anything contained in Article 10, the Licensee acknowledges and agrees that UBC may identify the title of this Agreement, the parties to this Agreement and the names of the
inventors of the Technology and any Improvements, and that UBC may also disclose to the inventors the amount of all payments made to UBC by the Licensee under this Agreement, the manner or method by which such payments were calculated and all
Payment Reports delivered to UBC by the Licensee in connection with such payments. 

  
 Page 13 of 32 

 UBC File:14-111 
  

10.5 Notwithstanding the termination or expiration of this Agreement, the rights and obligations in Article 10 survive and continue to bind the parties,
their successors and permitted assigns. 
  

	11.0	 PRODUCTION & MARKETING 

11.1 Neither party will use the Trade-marks or make reference to the other party in any advertising or publicity, without the prior written consent of
the other party. Without limitation, the parties will not issue a press release regarding this Agreement or the Technology or any Improvements without first obtaining the other party’s written approval, except when the Licensee is required by
law or regulations (including rules and regulations of the Securities Exchange Commission) to disclose such information, in which event the Licensee will provide UBC with sufficient prior notice to permit UBC to bring an application or other
proceeding to contest the requirement. 
 11.2 The Licensee represents and warrants to UBC that it has the infrastructure, expertise and resources to: 

 

	 	(a)	 develop and commercialize the Technology and any Improvements; 

 

	 	(b)	 track and monitor on an ongoing basis performance under the terms of each sublicense entered into by the Licensee;

  

	 	(c)	 monitor patent infringement regarding any patent relating to the Technology and any Improvements licensed under this
Agreement; and 

  

	 	(d)	 handle the Technology and any Improvements with care and without danger to the Licensee, its employees, agents, or the
public. 

  

	12.0	 ACCOUNTING RECORDS & REPORTS 

12.1 The Licensee will maintain at its principal place of business, or another place as may be most convenient, separate accounts and records of all
Revenues, Sublicensees and Sublicensing Revenues, and all business done in connection with the Technology or any Improvements or Products. The accounts and records will be in sufficient detail to enable proper returns to be made under this Agreement
and the Licensee will cause its Affiliated Companies and Sublicensees to keep (and provide to the Licensee and UBC) similar accounts and records. 
 12.2 The Licensee
will complete and deliver to UBC: 
  

	 	(a)	 within 30 days of each and every Royalty Due Date, a completed Payment Report in the form attached as Schedule
“B”, (or an amended form as required by UBC from time to time) together with the royalty payable under this Agreement. A separate Payment Report will be prepared and delivered for each Sublicensee, including an accounting statement
setting out in detail how the amount of Sublicensing Revenue received from the Sublicensee was determined and identifying each Sublicensee and the location of the business of each Sublicensee. The first Payment Report will be submitted within 30
days of the first Royalty Due Date after the receipt of the first Revenue or Sublicensing Revenue, and thereafter a Payment Report will be delivered every 6 months regardless of whether any Revenue or Sublicensing Revenue was received in the
preceding period; and 

  
 Page 14 of 32 

 UBC File:14-111 
  

	 	(b)	 on or before June 1 of each year during the Term, starting on June 1 2016, the relevant sections of an
Annual Report in the form attached as Schedule “C” (or an amended form as required by UBC from time to time). 

12.3 The calculation of Revenue, Sublicensing Revenue and royalties will be carried out in accordance with US GAAP applied on a consistent basis.

 12.4 The Licensee will retain the accounts and records referred to in Article 12.1 for at least 6 years from when they were made and will permit
any duly authorized representative of UBC to inspect, at UBC’s expense and no more frequently than once per calendar year, the accounts and records during the Licensee’s normal business hours. The Licensee will provide to the
representative all reasonable evidence necessary to verify the accounts and records and will allow copies to be made of the accounts, records and agreements. If an inspection of the Licensee’s records by UBC shows an under-reporting or
underpayment by the Licensee of any amount to UBC, by more than [***]% or $[***] (whichever is higher) for any 12 month period, then the Licensee will reimburse UBC for the cost of the inspection as well as pay to UBC any amount found due (including
any interest) within 30 days of notice by UBC to the Licensee. 
 12.5 UBC will use reasonable efforts to ensure that all information provided to UBC
or its representatives under this Article 12 remains confidential and is treated as confidential by UBC. 
  

	13.0	 INSURANCE 

13.1 During the Term (and for a period which is the longer of either [***] years after the end of the Term, or [***] years after the last Product is
sold) the Licensee will procure and maintain insurance (including public liability and commercial general liability insurance), as would be acquired by a reasonable and prudent businessperson carrying on a similar line of business. 

13.2 Notwithstanding Article 13.1, one month before the earlier of the start of any clinical Product testing that will have an effect on,
or will influence, human health, diagnosis, or treatment (“Human Clinical Trials”) or the First Use of the Technology or any Improvement, the Licensee will give notice to UBC of the terms and amount of the product liability,
clinical trials, public liability, and commercial general liability insurance and such other types of insurance which it has placed. This insurance will: 
  

	 	(a)	 be placed with a reputable and financially secure insurance carrier; 

 

	 	(b)	 include UBC, its Board of Governors, faculty, officers, employees, students and agents as additional insureds with a
severability of interest and cross-liability clauses; 

  

	 	(c)	 provide coverage regarding all activities under this Agreement; 

 

	 	(d)	 provide that the policy cannot be cancelled or materially altered except on at least 30 days’ prior notice to
UBC. 

 13.3 The Licensee will provide to UBC certificates of insurance evidencing the coverage 7 days before the earlier of any
Human Clinical Trials or the First Use of the Technology. The Licensee will not: 
  

	 	(a)	 start any Human Clinical Trials, 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 15 of 32 

 UBC File:14-111 
  

	 	(b)	 allow the First Use of the Technology or any Improvement to occur; or 

 

	 	(c)	 sell any Product or allow any third party to use the Technology or any Improvement, 

at any time unless an insurance certificate is provided to UBC, and the insurance outlined in Article 13.2 is in effect. 

13.4 The Licensee will also require each Sublicensee to procure and maintain: 
  

	 	(a)	 public liability and commercial general liability insurance and such other types of insurance as would be acquired by
a reasonable and prudent businessperson carrying on a similar line of business; and 

  

	 	(b)	 in any event, one month before the earlier of any Human Clinical Trials or the First Use of the Technology or any
Improvement by the Sublicensee, product liability, clinical trials, public liability and commercial general liability insurance in reasonable amounts, with a reputable and financially secure insurance carrier. 

13.5 The Licensee will ensure that all Sublicensees’ policies of insurance include UBC, its Board of Governors, faculty, officers, employees,
students and agents as additional insureds. 
  

	14.0	 ASSIGNMENT 

14.1 Subject to Article 14.2, the Licensee will not assign, transfer or otherwise dispose of any or all of the rights granted to it under this Agreement
without the prior written consent of UBC, such consent not to be unreasonably withheld. 
 14.2 The Licensee may assign this Agreement as part of a
sale, transfer or merger of the Licensee’s entire business (or that part of Licensee’s business that exercises all rights granted under this Agreement. 

14.3 UBC will have the right to assign its rights, duties and obligations under this Agreement to a company of which it is the sole shareholder, or a
society which it has incorporated or which has purposes which are consistent with the objectives of UBC. If UBC makes such an assignment, the Licensee will release and discharge UBC from all obligations or covenants, provided that the company or
society, as the case may be, signs a written agreement which provides that the company or society assumes all obligations or covenants from UBC and that the Licensee retains all rights granted to the Licensee under this Agreement. 

 

	15.0	 GOVERNING LAW 

15.1 This Agreement is governed by, and will be construed in accordance with, the laws of British Columbia and the laws of Canada in force in that
province, without regard to its conflict of law rules. All parties agree that by executing this Agreement they have attorned to the jurisdiction of the Supreme Court of British Columbia. The parties agree that the British Columbia Supreme Court has
exclusive jurisdiction over this Agreement. 
  

	16.0	 NOTICES 

16.1 All reports and notices or other documents that a party is required or may want to deliver to any other party will be delivered: 

  
 Page 16 of 32 

 UBC File:14-111 
  

 

	 	(a)	 in writing; and 

  

	 	(b)	 either by personal delivery or by registered or certified mail at the address for the receiving party set out in
Article 16.2 or as varied by any notice. 

 Any notice personally delivered is deemed to have been received at the time of delivery.
Any notice mailed in accordance with this Article 16.1 is deemed to have been received at the end of the fifth day after it is posted. 
 16.2 The
address for delivery of notices and instructions for making payments to UBC are set out in the attached Schedule “D”. The address for delivery of notices to the Licensee is set out below: 

GenomeDx Biosciences 

1038 Homer St. 

Vancouver, BC V6B 2W9 
  

	 	Telephone:	 1.888.792.1601 

	 	Fax:	 1.855.324.2768 

  

	17.0	 TERM 

17.1 The term (the “Term”) of this Agreement starts on the Start Date and ends on the date on which all payment
obligations expire, upon which time the license to Licensee shall become fully-paid, royalty free, perpetual and irrevocable. 
  

	18.0	 TERMINATION OF AGREEMENT 

18.1 This Agreement automatically and immediately terminates without notice to the Licensee if any proceeding under the Bankruptcy and Insolvency Act of
Canada, or any other statute of similar purpose, is started by or against the Licensee and is not dismissed within 90 days. 
 18.2 UBC may, at its
option, terminate this Agreement by giving notice to the Licensee if one or more of the following occurs: 
  

	 	(a)	 the Licensee becomes insolvent, as evidenced for example (without limitation) by the appointment of a receiver or
receiver manager; 

  

	 	(b)	 any execution or other process of any court becomes enforceable against the Licensee, or if any similar process is
levied on the rights under this Agreement or on any money due to UBC and is not released or satisfied by the Licensee within 30 days from the process becoming enforceable or being levied; or 

 

	 	(c)	 any resolution is passed or order made or other steps taken for the winding up, liquidation or other termination of
the existence of the Licensee. 

  

	 	(d)	 if the Licensee breaches any of Articles 4.1, 11.1 or 13.1; 

 

	 	(e)	 if the Licensee, or any Affiliated Company is in breach of any other agreement between the Licensee or such Affiliated
Company and UBC and the breach has not been cured within the time provided for the curing of the breach under the terms of the other agreement. 

  
 Page 17 of 32 

 UBC File:14-111 
  

18.3 Other than as set out in Article 18.1, either party may terminate this Agreement for any breach which is not remedied after providing the following
notice to the party in breach: 
  

	 	(a)	 60 days’ notice in the case of any breach which can reasonably be remedied within 60 days of the delivery of such
notice; or 

  

	 	(b)	 if the breach cannot be remedied within 60 days and the breach is not remedied within such further period as may be
reasonably necessary, or within 90 days after receipt of notice, whichever is sooner. 

 18.4 If this Agreement is terminated under
Article 18.1, 18.2 or 18.3, the Licensee will make all outstanding royalty-payments to UBC under Articles 5 and 6, and UBC may proceed to enforce payment of all outstanding royalties or other monies owed to UBC and to exercise any or all of the
rights and remedies available under this Agreement or otherwise available by law or in equity, successively or concurrently, at the option of UBC. Within 5 days of the Effective Termination Date, the Licensee will deliver to UBC all Technology and
any Improvements in its possession or control and has no further right of any nature at all in the Technology or any Improvements. If the Licensee has not delivered up the Technology and any Improvements within 5 days from the Effective Termination
Date, UBC may immediately and without notice enter the Licensee’s premises and take possession of the Technology and any Improvements. The Licensee will pay all charges or expenses incurred by UBC in the enforcement of its rights or remedies
against the Licensee under this Article 18.4, including without limitation UBC’s legal fees and disbursements on an indemnity basis. 
 18.5 The
Licensee and all Sublicensees will cease to use the Technology or any Improvements in any manner at all or to manufacture or sell the Products within 5 days from the Effective Termination Date. The Licensee will then deliver to UBC an accounting
within 30 days from the Effective Termination Date. The accounting will specify, in or on such terms as UBC may in its sole discretion require, the inventory or stock of Products manufactured and remaining unsold on the Effective Termination Date.
UBC will instruct that the unsold Products be stored, destroyed or sold under its direction, provided this Agreement was terminated under Article 18.2 or 18.3. Without limitation, if this Agreement is terminated under Article 18.1, no Products will
be sold without the prior written consent of UBC. The Licensee will continue to make royalty payments to UBC in the same manner specified in Articles 5 and 6 on all Products that are sold in accordance with this Article 18.5, notwithstanding
anything contained in, or any exercise of rights by UBC, under Article-18.4. 
 18.6 Notwithstanding the termination or expiration of this Agreement,
Article 12 remains in full force and effect until 6 years after: 
  

	 	(a)	 all payments of royalty required to be made by the Licensee to UBC under this Agreement have been made by the Licensee
to UBC; and 

  

	 	(b)	 any other claim or claims of any nature or kind at all of UBC against the Licensee has been settled.

  

	19.0	 MISCELLANEOUS COVENANTS OF LICENSEE 

19.1 The Licensee represents and warrants to UBC that the Licensee is a corporation duly organized, existing and in good standing under the laws of
British Columbia and has the power, authority and capacity to enter into this Agreement and to carry out the transactions 

  
 Page 18 of 32 

 UBC File:14-111 
  

contemplated by this Agreement, all of which have been duly and validly authorized by all requisite corporate proceedings. 

19.2 The Licensee will comply with all laws, regulations and ordinances, whether Federal, State, Provincial, County, Municipal or otherwise, with
respect to the Technology and any Improvements and this Agreement. 
 19.3 The Licensee will pay all taxes and any related interest or penalty
designated in any manner at all and imposed as a result of the existence or operation of this Agreement, including without limitation tax which the Licensee is required to withhold or deduct from payments to UBC, but not any taxes based on
UBC’s income. he Licensee will provide to UBC evidence as may be required by Canadian authorities to establish that the tax has been paid. The royalties specified in this Agreement are exclusive of taxes. f UBC is required to collect a tax to
be paid by the Licensee or any of its Sublicensees, the Licensee will pay the tax to UBC on demand. 
 19.4 The obligation of the Licensee to make all
payments under this Agreement is absolute and unconditional and is not, except as expressly set out in this Agreement, affected by any circumstance, including without limitation any set-off, compensation, counterclaim, recoupment, defence or other
right which the Licensee may have against UBC, or anyone else for any reason at all. 
 19.5 The Licensee will pay interest on all undisputed amounts
due and owing to UBC under this Agreement but not paid by the Licensee on the due date, at the rate of [***]% per annum, calculated annually not in advance. The interest accrues on the balance of unpaid amounts from time to time outstanding, from
the date on which portions of the amounts become due and owing until payment in full. 
  

	20.0	 MANAGEMENT OF CONFLICTS OF INTEREST 

20.1 The Licensee acknowledges that it is aware of UBC’s Conflict of Interest Policy #97, Patent and Licensing Policy #88 and Research Policy #87
(www.universitycounsel.ubc.ca/policies/policies.html), and that UBC may amend these policies or introduce new policies from time to time 
  

	20.2	 Subject to Article 20.3 the Licensee and UBC agree, that: 

 

	 	(a)	 the facilities and research programs of the Licensee will be conducted independently of all UBC facilities, faculty,
students or staff, and in particular, independently of and from the Investigator and the laboratory facilities made available to the Investigator by reason of the Investigator’s employment at UBC; 

 

	 	(b)	 no students, post-doctoral fellows or other UBC staff will participate or be involved in the Licensee’s research,
projects or utilize its facilities; and 

  

	 	(c)	 any disclosures of inventions made by the Investigator to the Licensee will be immediately forwarded by the Licensee
to UBC. 

 20.3 The Licensee and UBC may, from time to time, enter into written agreements to permit activities which would
otherwise be prohibited by Article 20.2. 

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 19 of 32 

 UBC File:14-111 
  

21.0 GENERAL 
 21.1 Nothing contained in this Agreement
is to be deemed or construed to create between the parties a partnership or joint venture. No party has the authority to act on behalf of any other party, or to commit any other party in any manner at all or cause any other party’s name to be
used in any way not specifically authorized by this Agreement. 
 21.2 Subject to the limitations in this Agreement, this Agreement operates for the
benefit of and is binding on the parties and their respective successors and permitted assigns. 
 21.3 No condoning, excusing or overlooking by any
party of any default, breach or non-observance by any other party at any time or times regarding any terms of this Agreement operates as a waiver of that party’s rights under this Agreement. A waiver of
any term, or right under, this Agreement will be in writing signed by the party entitled to the benefit of that term or right, and is effective only to the extent set out in the written waiver. 

21.4 No exercise of a specific right or remedy by any party precludes it from or prejudices it in exercising another right or pursuing another remedy or
maintaining an action to which it may otherwise be entitled either at law or in equity. 
 21.5 All terms which require performance by the parties
after the expiry or termination of this Agreement, will remain in force despite this Agreement’s expiry or termination for any reason. 
 21.6
Part or all of any Article that is indefinite, invalid, illegal or otherwise voidable or unenforceable may be severed and the balance of this Agreement will continue in full force and effect. 

21.7 The Licensee acknowledges that the law firm of Richards Buell Sutton LLP has acted solely for UBC in connection with this Agreement and that all
other parties have been advised to seek independent legal advice. 
 21.8 This Agreement sets out the entire understanding between the parties and no
changes are binding unless signed in writing by the parties to this Agreement. 
 21.9 Time is of the essence of this Agreement. 

  
 Page 20 of 32 

 UBC File:14-111 

21.10 Unless the contrary intention appears, the singular includes the plural and vice versa and words importing a gender include other genders. 

SIGNED BY THE PARTIES AS AN AGREEMENT on the 4th            
day of February            , 2015 but effective as of the Start Date. 
 SIGNED FOR AND ON BEHALF
of 
 THE UNIVERSITY OF BRITISH COLUMBIA 
  

					
	 by its authorized signatories:
	  	 J.P. Heale, PhD, MBA

Interim Managing Director
 University-Industry Liaison Office
	  	

  

					
	 /s/ J. P. Heale
	 		 	
	  
 Authorized Signatory
	 		 	
	  
  

Authorized Signatory
	 		 	

 SIGNED FOR AND ON BEHALF of GENOMEDX 

BIOSCIENCES INC. 

					
	  
 by its authorized
signatories:
	 		 	
	  
 /s/ David Matthews
	 		 	
	  
 Authorized Signatory
	 		 	
			
	 David Matthews
	 		 	
			
	 Please print Name and Title of Signatory
	 		 	
			
	  
  

Authorized Signatory
	 		 	
			
	  
  

Please print Name and Title of Signatory
	 		 	

  
 Page 21 of 32 

 SCHEDULE “A” 

DESCRIPTION OF “TECHNOLOGY” 
  

							
	 [***]
	 	[***]	 	[***]	 	[***]
	
[***]
	 	[***]	 	[***]	 	[***]

  

	
	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
	Page 22 of 32

 SCHEDULE “B” 

Payment Report for the Period dd/mm/yy to dd/mm/yy 

Instructions for Completing this Report 
 Please fill out
each section in full, identifying in Royalty Summary Table the unit sales and geographical sales areas. If the license with UBC involves several product lines, please prepare a separate Summary Table for each product line. For Sublicensing Revenue
received from any Sublicensee, please prepare an additional report for each such Sublicensee. 
 PLEASE NOTE: An interest rate of [***]% per
annum, calculated annually not in advance will be assessed against all payments in arrears. 
  

											
	 Licensee
	 		 	Agreement #	 		 	UBC ID #	 	
	(or Sublicensee)	 	  
	 		 	  
	 		 	  

											
		
	UBC Technology	 	  

		
	Report Type (check one and complete as appropriate)	 	

											
		
	Single Product Line    ☐ Product Line Trade Name	 	  

											
		
	Multiple Products        ☐ Page        Of    
    Product Line Trade Name	 	  

											
		
	Sublicensee Report    ☐ Page        Of       	 	

   Payments this Quarter please complete separate tables for multiple product lines) Royalties on Product
Sales 
  

																							
	Country	  	Units
Sold	  	Unit Price
(domestic
currency)	  	Gross	  	Less
Allow-
ances*	  	Net	  	Royalty
Rate	  	Conversion
Rate (to
Canadian $)	  	Period Royalty
Amount (Canadian $)	 
	  	This yr	 	  	Last yr	 
	 Canada

US
 Europe

(specify countries)
  

Other
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	 	 	  	 	 	 
		  		  		  		  		  		  	Total Product Royalties	  	 	 	 	  	 	 	 

 Additional Payments (complete all that apply) 
  

															
	 Milestone Payment
	 	        	 		  	Amount  	  	 	  	 	  			
	 Annual License Fee
	 	 	 		  	Amount  	  	 	  	 	  			
		 		 		  		  	This Year	  	Last Year	  			
		 		 	 Total Payments for Period  
	  	 	  	 	  	 	    	 

 *Please indicate the reasons for returns or other allowances, if significant. Please note any unusual occurrences that
affected royalty amounts during the period. 
 Prepared by
                                         
                        Date
Dd/mm/yy                 Phone
                                         
                        
 I
                         (print name),
                             (title) hereby certify the foregoing information as true and correct.

  

	
	
               
                                         
                                         
                     

	Signature
                                         
                Date
Signed                        

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 23 of 32 

 UBC File:14-111 
  

SCHEDULE “C” 
 UBC License
Agreement Annual Report 
 The information to be completed below will constitute the annual report required under the UBC License Agreement. Any
information or documents provided by the Licensee in this report will not be interpreted as affecting the express rights and obligations of the Licensee contained in the License Agreement. This report is in addition to the Payment Report to
accompany each royalty payment. 
 Date of Report:
                                      Person Preparing This
Report:                                      

Name of Licensee:
                                 UBC File Number:    
                                 

Jurisdiction of Corporation:
                                         
                        Head Office
                                 

                            
                                         
                                        Address:
                                 

Contact Person for Company     
                                         
                                         
       
 Licensed Technology:
                                         
                                         
           
 Telephone Number:
                                        
     E-mail Address:
                                        

  

	1.	 Please provide a brief report on the status of development of the UBC Technology, progress on creating a commercial
Product or subsequent marketing of the Product as appropriate. 

  

	
	  
  

 

	2.	 Has the Licensee filed any patent applications for modifications or improvements relating to the original UBC
Technology? Please provide details, and attach copies of all relevant documents. 

  

	
	  
  

 

	3.	 Has the Licensee become aware of any potential 3rd party infringing on the UBC patents or related intellectual
property? If so please provide details and outline what the Licensee is doing about this. 

  

	
	  
  

 

	4.	 Has the Licensee met any milestone or performance objectives in the past year as set forth in the License Agreement?
Please outline the past year’s accomplishments 

  

	
	  
  

 

	5.	 Does the Licensee expect to meet any milestone or performance objective in the coming year as set forth in the License
Agreement? If so please provide details. 

  

	
	  
  

 

	6.	 Has the Licensee granted any sublicenses to 3rd parties? If so have copies of the sublicense agreement been provided
to the Technology Manager at UBC? If not, please enclose a copy of each proposed sublicense agreement. 

  

	
	  
  

 

	7.	 Has the Licensee made started any clinical trials or made any sales in the last 12 months? Yes
                         

No
                         

If so please submit a completed Royalty Payment Report. 

  
 Page 24 of 32 

 UBC File:14-111 
  

 

	 	a)	 Date of sales of Products utilizing the Technology; 

 

	 	b)	 Date of any clinical trials. 

 

	
	  
  

 

	8.	 Does your company have public liability insurance? If so, please attach a copy of the insurance policy naming UBC as
an insured as required by the License Agreement. 

  

	
	  
  

 

	9.	 Please provide the Licensee’s estimate or projection of gross sales revenue for products based on the UBC
Technology for the next 12 months by the Licensee and any sub-licensee. 

  

	
	  
  

 

	10.	 Is there any other information relating to this License that you think we should be aware of? Please summarize them
below or contact us directly. 

  

	
	  
  

Prepared by
                                         
    Date Dd/mm/yy      Phone
                                        
     
 I
                         (print name), of
                         (title) hereby certify the foregoing information as true and correct. 

 

	
	  

Signature
                                         
                                         
                                         
  Date Signed 
 Once completed, please submit this report to: 

Managing Director 

University — Industry Liaison Office 

#103 — 6190 Agronomy Road, 

Vancouver, BC 

V6T 1Z3 

  
 Page 25 of 32 

 SCHEDULE “D” 

ADDRESS FOR NOTICES & PAYMENT INSTRUCTIONS 
  

	1.	 The address for delivery of notices to UBC is: 

The Director 

University — Industry Liaison Office 

University of British Columbia 

#103 — 6190 Agronomy Road 

Vancouver, British Columbia 

V6T 1Z3 
 Telephone:
        (604) 822-8580 

Fax:                    (604)
822-8589 
  

	2.	 Payment of all amounts due to UBC under the terms of this license may be made as follows: 

 

	 	a)	 by cheque made payable to “The University of British Columbia” delivered to UBC at the above address; or

  

	 	b)	 by wire transfer in accordance with the instructions set out below: 

Note: Please ensure ALL of the information is provided for efficient receipt of wire payments: 

 

			
	    [***]
	  	 [***]

	 [***]
	  	
[***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]

 
 [***]

[***]
	  	 [***]

 
 [***]

[***]
  

	 	  	 [***]

 
 [***]

[***]

  
 [***]=CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 Page 26 of 32 

 SCHEDULE “E” 

PATENT CLIENT AND BILLING AGREEMENT 
 BETWEEN:

 THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British
Columbia with offices at #103-6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3 (“UBC”) 
 AND: 

GENOMEDX BIOSCIENCES INC., a corporation incorporated under the Business Incorporation Act of British Columbia, with its
offices at 201-1595 W. 3rd Ave., Vancouver, BC, V6J 1J8 (“Licensee”) 
 AND: 

<->, a law firm with offices at <-> (the “Firm”) 

WHEREAS: 
 A. The Licensee and UBC have entered into a license
agreement under which UBC has licensed to the Licensee certain technology including the patents and patent applications listed in Appendix 1 (the “Patents”); 

B. UBC and the Licensee will use the Firm to prepare, file, prosecute and maintain the Patents; 

C. UBC will be the client of the Firm; and 
 D. UBC, the Licensee,
and the Firm have agreed to enter into this agreement to confirm the terms on which the Firm will be engaged to prepare, file, prosecute and maintain the Patents. 

THE PARTIES AGREE AS FOLLOWS: 
 1. While UBC is the client of
the Firm, UBC hereby authorizes the Firm to obtain and act in accordance with instructions directly from the Licensee (or its patent counsel) on all matters related to the preparation, filing, prosecution and maintenance of the Patents. The Firm
will copy UBC on all material documents and correspondence. 
 2. The Licensee is responsible for the payment of all fees, charges and disbursements
incurred by the Firm related to the preparation, filing, prosecution and maintenance of the Patents. The Firm will invoice the Licensee and will copy UBC on all such invoices. The Licensee will pay the Firm directly for all such fees, charges and
disbursements, and will copy UBC on each payment made. 
 3. Notices and copies of all documents and correspondence should be sent to the following:

  

							
		 	 To UBC:
	 	 Associate Director
	 	
		 		 	 University — Industry Liaison Office

		 		 	 The University of British Columbia

  
 Page 27 of 32 

							
		 		 	 #103 — 6190 Agronomy Road

		 		 	 Vancouver, British Columbia

		 		 	 V6T 1Z3
	 	
		 		 	 Telephone:
	 	 (604) 822-8580

		 		 	 Fax:
	 	 (604) 822-8589

				
		 	 To the Licensee:
	 	 <->
	 	
		 		 	 <->
	 	
		 		 	 Telephone:
	 	 <-> (

		 		 	 Fax:
	 	 <-> (

				
		 	 To the Firm:
	 	 <->
	 	
		 		 	 <->
	 	
		 		 	 Telephone:
	 	 <-> (

		 		 	 Fax:
	 	 <-> (

 SIGNED BY THE PARTIES AS AN AGREEMENT on the
                 day of
                                         
                           , 20     

 

					
			
	 THE UNIVERSITY OF BRITISH
	 	 )
	  	
	 COLUMBIA by its authorized signatory:
	 		  	
	     
	 		  	
		 	)	  	
	     
	 		  	
		 	)	  	
	     
	 		  	
	
                        
                                         
           
	 	)	  	
	     
	 		  	
	 Authorized Signatory
	 	)	  	
			
	 GENOMEDX BIOSCIENCES INC. by its
	 	)	  	
	 authorized signatory:
	 		  	
		 	)	  	
		 		  	
		 	)	  	
		 		  	
	
                        
                                         
           
	 	)	  	
			
	 Authorized Signatory
	 	)	  	
			
	 <            > by its authorized signatory:
	 	)	  	
	     
	 		  	
		 	)	  	
	     
	 		  	
		 	)	  	
		 		  	
	
                        
                                         
           
	 	)	  	
		 		  	

  
 Page 28 of 32 

					
	
                        
                                         
           
	 		  	
			
	 Authorized Signatory
	 	)	  	

  
  

Appendix “1” 
 List of Patents 

  
 Page 29 of 32 

 SCHEDULE “F” 

LIST OF LICENSED AFFILIATED COMPANIES 

  
 Page 30 of 32 

 SCHEDULE “G” 

MANDATORY SUBLICENSING PROVISIONS 
 The
Licensee (but not the Licensee’s Affiliated Companies) may grant sublicense agreements to Sublicensees without the prior written consent of UBC, provided that each such sublicense agreement (a “Sublicense Agreement”) meets the
requirements set out in the UBC - GenomeDx head license agreement (the “UBC License Agreement”) for sublicenses and the provisions of this Schedule “G”: 

 

	1.	 The Sublicensee shall acknowledge all ownership of the sublicensed Technology and any Improvements as set out in the
UBC License Agreement. 

  

	2.	 The Sublicensee shall acknowledge that UBC has the right to use the Technology and any Improvements without charge in
any manner at all for internal non-commercial research, scholarly publication, educational and other non-commercial uses, all in accordance with the terms of the UBC License Agreement. 

 

	3.	 Publication and Confidentiality: The Sublicensee shall comply with the publication and confidentiality obligations
with respect to UBC’s Confidential Information in accordance with Article 10 of the UBC License Agreement. 

  

	4.	 The Sublicensee shall agree not to use UBC’s name, trade-marks, service marks, logos, insignia, seal, or designs
without the prior written consent of UBC, except in a manner as permitted under Article 11.1 of the UBC License Agreement. 

  

	5.	 The Sublicensee shall procure and maintain insurance in full compliance with the terms of the UBC License Agreement
and will include UBC, its Board of Governors, faculty, officers, employees, students and agents as additional insured under the Sublicensee’s insurance. 

  

	6.	 The Sublicensee shall acknowledge and agree that UBC makes no representations, conditions or warranties, either
express or implied, regarding the Technology, Improvements or the Products. Without limitation, the Sublicensee shall acknowledge and agree that UBC specifically disclaims any implied warranty, condition or representation that the Technology,
Improvements or the Products: 

  

	 	(I)	 correspond with a particular description; 

 

	 	(ii)	 are of merchantable quality; 

 

	 	(iii)	 are fit for a particular purpose; or 

 

	 	(iv)	 are durable for a reasonable period of time. 

The Sublicensee shall acknowledge and agree that UBC is not liable for any loss, whether direct, consequential, incidental or special,
which the Sublicensee or other third parties suffer arising from any defect, error or fault of the Technology, Improvements or Products, or their failure to perform, even if UBC is aware of the possibility of the defect, error, fault or failure. The
Sublicensee shall acknowledge that it has been advised to undertake its own due diligence regarding the Technology, Improvements, and Products. 
  

	7.	 The Sublicensee shall acknowledge and agree that: 

 

	 	(a)	 UBC makes no warranty or representation as to title to the Technology or any Improvements or that anything made, used,
sold or otherwise disposed of under the Sublicense Agreement will not infringe the patents, copyrights, trade-marks, industrial designs or other intellectual property rights of any third parties, or any patents, copyrights, trade-marks, industrial
design or other intellectual property 

  
 Page 31 of 32 

	 	 
rights owned, in whole or in part, by UBC, or licensed by UBC to any third parties; 

  

	 	(b)	 UBC makes no express or implied warranty or representation that the Sublicensee has, or will have the freedom to
operate or practice the Technology or any Improvements, or the freedom to make, have made, use, sell or otherwise dispose of Products; or 

  

	 	(c)	 there is no obligation on UBC to bring, prosecute or defend actions or suits against third parties for infringement of
patents, copyrights, trade-marks, industrial designs or other intellectual property or contractual rights. 

  

	8.	 The Sublicensee shall indemnify, hold harmless and defend UBC and its Board of Governors, officers, employees,
faculty, students, invitees and agents against any and all claims (including all associated legal fees and disbursements actually incurred) arising out of the exercise by Sublicensee of any rights under the Sublicense Agreement, including without
limitation against any damages or losses, consequential or otherwise, arising in any manner at all from or out of the use of the Technology, Improvements or Products by the Sublicensee, or the Sublicensee’s Affiliated Companies,
sub-sublicensees or any of their respective customers or end-users. 

  

	9.	 The Sublicensee shall agree that UBC’s total liability, whether under the express or implied terms of the UBC
License Agreement or the Sublicense Agreement, in tort (including negligence) or at common law, for any loss or damage suffered by the Sublicensee, whether direct, indirect or special, or any other similar damage that may arise or does arise from
any breaches of the UBC License Agreement by UBC, its Board of Governors, officers, employees, faculty, students or agents, is limited to the amount of $[***] (Canadian funds). 

 

	10.	 The Sublicensee shall also acknowledge and agree that UBC will not be liable for consequential or incidental damages
arising from any breach or breaches of the UBC License Agreement or the Sublicense Agreement. 

  

	11.	 The Sublicensee shall acknowledge that in consideration of the grant of the Sublicense Agreement and the grant
thereunder of a sublicense to UBC’s interest in the Technology and Improvements, UBC shall, as a third party beneficiary, be entitled to enforce against the Sublicensee at UBC’s discretion, and for UBC’s benefit, those provisions
contained in the Sublicense Agreement for UBC’s benefit. 

 [***]=CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

  
 Page 32 of 32Exhibit 10.1

Second AMENDED AND RESTATED PROMISSORY NOTE
	Borrower:
	Amcon Distributing Company
7405 Irvington Road
Omaha, NE 68122
	Lender:
	BMO Harris Bank N.A.
111 W. Monroe Street
Chicago, IL 60603 4095

	Principal Amount:  $4,765,058.22
	Date: December 22, 2020

​
Promise To Pay.  Amcon Distributing Company (“Borrower”) promises to pay to BMO Harris Bank N.A. (“Lender”), or order, in lawful money of the United States of America, the principal amount of Four Million Seven Hundred Sixty-Five Thousand Fifty-Eight and 22/100 Dollars ($4,765,058.22), together with interest at the rate of 3.625% per annum on the unpaid principal balance until paid in full.
Payment.  Borrower will pay this loan in regular principal and interest payments of $47,399.00 each payment and one irregular last payment of all remaining outstanding principal and interest outstanding hereunder. Borrower's first principal payment is due on February 1, 2021, and all subsequent principal and interest payments are due on the same day of each month after that. Borrower's final payment will be due on the earlier of (i) March 20, 2025 or (ii) the date on which Lender is no longer a participating lender under any loan facility, other than the loan facility evidenced by this Note (the “Other Loan Facilities”), provided that if Lender is no longer a participant in the Other Loan Facilities due to Lender’s assignment of its participating interest(s) in all Other Loan Facilities, then the final payment date shall not be accelerated and shall be March 20, 2025.   Such final payment, on whichever date it occurs, will be for all principal and all accrued interest not yet paid.  Borrower will pay Lender at Lender's address shown above or at such other place as Lender may designate in writing.  Payments received by Lender shall be applied first to accrued interest then due and then to the outstanding principal balance of this Note unless otherwise directed, provided that after an Event of Default (as defined below) all payments received shall be applied in such order and manner as Lender shall determine.  If any payment from Borrower under this Note becomes due on a day that is not a Business Day (as defined below), such payment shall be made on the next Business Day and any such extension shall be included in computing interest under this Note.
Under no circumstances will the interest rate on this Note be more than the maximum rate allowed by applicable law.
Computation of Interest.  All interest on this Note shall be computed on a 365/360 basis; that is, by applying the ratio of the interest rate over a year of 360 days, multiplied by the outstanding principal balance, multiplied by the actual numbers of days the principal balance is outstanding. All interest payable under this Note is computed using this method.  This calculation method results in a higher effective interest rate than the numeric interest rate stated in this Note.
Prepayment.  Borrower may pay all or a portion of the amount owed earlier than it is due at any time without penalty or fee. 

	​
	​
	​

​

Early payments will not, unless agreed to by Lender in writing, relieve Borrower of Borrower's obligation to continue to make payments under the payment schedule.  Rather, early payments will reduce the principal balance due and may result in Borrower's making fewer payments.  Borrower agrees not to send Lender payments marked “paid in full”, “without recourse”, or similar language.  If Borrower sends such a payment, Lender may accept it without losing any of Lender's rights under this Note, and Borrower will remain obligated to pay any further amount owed to Lender.  All written communications concerning disputed amounts, including any check or other payment instrument that indicates that the payment constitutes “payment in full” of the amount owed or that is tendered with other conditions or limitations or as full satisfaction of a disputed amount must be mailed or delivered to:  BMO Harris Bank N.A., 111 W. Monroe Street, Chicago, IL 60603 4095.
Late Charge.  If a payment is 10 days or more late, Borrower will be charged 5.000% of the regularly scheduled payment or $15.00, whichever is greater. 
Default.  Each of the following shall constitute an event of default (“Event of Default”) under this Note:
Payment Default.  Borrower fails to make any payment when due under this Note.
Other Defaults.  Borrower fails to comply with or to perform any other term, obligation, covenant or condition contained in this Note or in any of the related documents or to comply with or to perform any term, obligation, covenant or condition contained in any other agreement between Lender and Borrower, including, without limitation, the Other Loan Facilities.
Default in Favor of Third Parties.  Borrower, or any other party thereto, defaults under any loan, extension of credit, security agreement, purchase or sales agreement, or any other agreement, in favor of any other creditor or person that may materially affect any of Borrower's property or Borrower's ability to repay this Note or perform Borrower's obligations under this Note or any of the related documents.
False Statements.  Any warranty, representation or statement made or furnished to Lender by Borrower or on Borrower's behalf under this Note or the related documents is false or misleading in any material respect, either now or at the time made or furnished or becomes false or misleading at any time thereafter.
Insolvency.  The dissolution or termination of Borrower's existence as a going business, the insolvency of Borrower, the appointment of a receiver for any part of Borrower's property, any assignment of the benefit of creditors, any type of creditor workout, or the commencement of any proceeding under any bankruptcy or insolvency laws by or against Borrower.
Creditor or Forfeiture Proceedings.  Commencement of foreclosure or forfeiture proceedings, whether by judicial proceeding, self-help, repossession or any other method, by any creditor of Borrower or by any governmental agency against any collateral securing the loan.  This includes a garnishment of any of Borrower's accounts, including deposit accounts, with Lender.  However, this Event of Default shall not apply if there is a good faith dispute by Borrower as to the validity or reasonableness of the claim which is the basis of the creditor or forfeiture proceeding and if Borrower gives Lender written notice of the creditor or forfeiture proceeding and deposits 

	​
	2
	​

​

with Lender monies or a surety bond for the creditor or forfeiture proceeding, in an amount determined by Lender, in its sole discretion, as being an adequate reserve or bond for the dispute.
Events Affecting Guarantor.  Any of the preceding events occurs with respect to any guarantor, endorser, surety, or accommodation party of any of the indebtedness or any guarantor, endorser, surety, or accommodation party dies or becomes incompetent, or revokes or disputes the validity of, or liability under, any guaranty of the indebtedness evidenced by this Note.
Change in Ownership.  Any change in ownership of twenty-five percent (25%) or more of the common stock of Borrower.
Adverse Change.  A material adverse change occurs in Borrower's financial condition, or Lender believes the prospect of payment or performance of this Note is impaired.
Insecurity.  Lender in good faith believes itself insecure.
Lender's Rights.  Upon the occurrence of any Event of Default, Lender may declare the entire unpaid principal balance under this Note and all accrued unpaid interest immediately due, and then Borrower will pay that amount.  Also in any such event Lender shall have the right to exercise any other action, right, power or remedy provided for in any other instrument or agreement with Lender or as otherwise permitted by applicable law.
Attorneys' Fees; Expenses.  Lender may hire or pay someone else to help collect this Note if Borrower does not pay.  Borrower will pay Lender that amount.  This includes, subject to any limits under applicable law, Lender's attorneys' fees and Lender's legal expenses, whether or not there is a lawsuit, including attorneys' fees, expenses for bankruptcy proceedings (including efforts to modify or vacate any automatic stay or injunction), and appeals.  If not prohibited by applicable law, Borrower also will pay any court costs, in addition to all other sums provided by law.
Jury Waiver.  Lender and Borrower hereby waive the right to any jury trial in any action, proceeding, or counterclaim brought by either Lender or Borrower against the other.
Governing Law.  This Note will be governed by federal law applicable to Lender and, to the extent not preempted by federal law, the laws of the State of Illinois without regard to its conflicts of law provisions.  This Note has been accepted by Lender in the State of Illinois. 
Choice of Venue.  If there is a lawsuit, Borrower agrees upon Lender's request to submit to the jurisdiction of the courts of Cook County, State of Illinois. 
Right of Setoff.  To the extent permitted by applicable law, Lender reserves a right of setoff in all Borrower's accounts with Lender (whether checking, savings, or some other account).  This includes all accounts Borrower holds jointly with someone else and all accounts Borrower may open in the future.  However, this does not include any accounts for which setoff would be prohibited by law.  Borrower authorizes Lender, to the extent permitted by applicable law, to charge or setoff all sums owing on the debt against any and all such accounts, and, at Lender's option, to administratively freeze all such accounts to allow Lender to protect Lender's charge and setoff rights provided in this paragraph. 

	​
	3
	​

​

Collateral. Borrower acknowledges this Note is secured by among other things, that certain Amended and Restated Mortgage and Security Agreement with Assignment of Rents, dated as of September, 2016, on real property located at 2517 Ellington Road, Quincy, IL 62305 and recorded in the public records of Adams County, Illinois, as such mortgage is amended as of the date hereof, that certain Amended and Restated Mortgage and Security Agreement with Assignment of Rents, dated as of September, 2016, on real property located at 1511 Turbine Drive, Rapid City, SD, and recorded in the public records of Pennington County. South Dakota, as such mortgage is amended as of the date hereof and that certain Amended and Restated Mortgage and Security Agreement with Assignment of Rents, dated as of September, 2016, on real property located at 3125 East Thayer Avenue, Bismarck, ND 58501 and recorded in the public records of Burleigh County, North Dakota, as such mortgage is amended as of the date hereof.
Payment Amount after Default. Whenever increases occur in the interest rate due to an event of default, Lender, at its option, may do one or more of the following: (A) increase Borrower's payments to ensure Borrower's loan will pay off by its original final maturity date, (B) increase Borrower's payments to cover accruing interest, (C) increase the number of Borrower's payments, and (D) continue Borrower's payments at the same amount and increase Borrower's final payment.
Amended and Restated.  This is a restatement of the indebtedness evidenced by, and is a replacement of, that certain Amended and Restated Promissory Note of the undersigned dated September 30, 2016 in the face principal amount of $3,384,319.00 payable to the order of the Lender, and nothing contained herein shall be construed (i) to deem paid or forgiven the unpaid principal amount of, or unpaid accrued interest on, said Promissory Note outstanding at the time of its replacement by this Note or (ii) to release, cancel, terminate or otherwise adversely affect all or any part of any lien, security interest or other encumbrance heretofore granted to or for the benefit of the payee of said Promissory Note which has not otherwise been expressly released.
Amendments and/or Modifications.  Lender shall not be deemed to have waived any rights under this Note unless such waiver is given in writing and signed by the Lender.  Notwithstanding any provision in this Note to the contrary, this Note may be modified by mutual consent of the Lender and Borrower.  
Successor Interests.  The terms of this Note shall be binding upon Borrower, and upon Borrower's successors and assigns, and shall inure to the benefit of Lender and its successors and assigns.
General Provisions.  If any part of this Note cannot be enforced, this fact will not affect the rest of the Note.  Lender may delay or forgo enforcing any of its rights or remedies under this Note without losing them.  Borrower and any other person who signs, guarantees or endorses this Note, to the extent allowed by law, waive presentment, demand for payment, and notice of dishonor.  Upon any change in the terms of this Note, and unless otherwise expressly stated in writing, no party who signs this Note, whether as maker, guarantor, accommodation maker or endorser, shall be released from liability.  All such parties agree that Lender may renew or extend (repeatedly and for any length of time) this loan or release any party or guarantor or collateral; or impair, fail to realize upon or perfect Lender's security interest in the collateral; and take any other action deemed necessary by Lender without the consent of or notice to anyone.  All such parties 

	​
	4
	​

​

also agree that Lender may modify this loan without the consent of or notice to anyone other than the party with whom the modification is made.  
*       *       *
​

	​
	5
	​

​

(Signature Page to Promissory Note-BMO Harris Bank N.A.)
​

PRIOR TO SIGNING THIS NOTE, BORROWER READ AND UNDERSTOOD ALL THE PROVISIONS OF THIS NOTE.  BORROWER AGREES TO THE TERMS OF THE NOTE.  
Executed by the undersigned as of the date first written above.
	​
	AMCON DISTRIBUTING COMPANY
By:​ ​/s/ Charles J. Schmaderer​ ​
Name:  Charles J. Schmaderer

Title:

Vice President and Chief Financial Officer

​

	​
	​
	​

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]